Galit Alter

{{Short description|Immunologist and virologist}}

{{Infobox scientist

|name = Galit Alter

|birth_name =

|image =

|birth_date = {{birth based on age as of date|43|2020|12|10}}{{cite news|url= https://www.bostonglobe.com/2020/12/10/magazine/galit-alter-connecting-scientists-speed-up-covid-19-fight/ |title= Galit Alter: Connecting scientists to speed up the COVID-19 fight |website= bostonglobe.com |first= Jessie |last= Scanlon |date= 2020-12-10 |access-date= 2021-02-23}}

|birth_place =

|death_date =

|death_place =

|residence =

|citizenship =

|nationality =

|religion =

|ethnicity =

|fields = immunology, infectious diseases

|workplaces = Harvard Medical School
Ragon Institute

| education = Ph.D. from McGill University{{cite web|url= https://www.hms.harvard.edu/dms/virology/fac/Alter.php |title= Virology Faculty Member - Galit Alter |website= hms.harvard.edu |access-date= 2021-02-23}}

|alma_mater =

| thesis_title =

| thesis_url =

| thesis_year =

| doctoral_advisor =

|doctoral_students =

|notable_students =

|known_for =

|influences =

|influenced =

|awards = MGH Research Scholars Award (twice){{cite web|url= https://www.ragoninstitute.org/portfolio-item/alter-lab/ |title= Alter - Ragon Institute of MGH, MIT and Harvard |website= ragoninstitute.org |access-date= 2021-02-23}}

|spouse =

|signature =

|website = {{URL|ragoninstitute.org/portfolio-item/alter-lab/}}

}}

Galit Alter is an immunologist and virologist, professor of medicine at Harvard Medical School, and group leader at the Ragon Institute of MGH, MIT and Harvard. She is known for her work on the expansion of particular natural killer cell subtypes in response to HIV-1 infection.{{cite journal |last1=Alter |first1=Galit |last2=Malenfant |first2=Jessica M |last3=Altfeld |first3=Marcus |title=CD107a as a functional marker for the identification of natural killer cell activity |journal=J Immunol Methods |date=2004 |volume=294 |issue=1–2 |pages=15–22 |doi=10.1016/j.jim.2004.08.008 |pmid=15604012 |url=https://pubmed.ncbi.nlm.nih.gov/15604012/ |access-date=1 April 2021}}{{cite journal |display-authors=2|last1=Alter |first1=Galit |last2=Martin |first2=Maureen P |last3=Teigen |first3=Nickolas |last4=Altfeld |first4=Marcus |title=Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes |journal=J Exp Med |date=26 Nov 2007 |volume=204 |issue=12 |pages=3027–36 |doi=10.1084/jem.20070695 |pmid=18025129 |pmc=2118524 |doi-access=free }} She has also contributed to the understanding of how SARS-CoV-2 antibody titers correlate with sustained humoral protection, including identifying coordinated immune cell-antibody signatures that may predict COVID-19 infection outcome.{{cite journal |last1=Atyeo |first1=Caroline |last2=Fischinger |first2=Stephanie |last3=Zohar|first3=Tomer... |last4=Alter |first4=Galit |title=Distinct Early Serological Signatures Track with SARS-CoV-2 Survival |journal=Immunity |date=15 September 2020 |volume=53 |issue=3 |pages=524–532 |doi=10.1016/j.immuni.2020.07.020 |pmid=32783920 |pmc=7392190 |doi-access=free }}

From October 2022 to October 2024 she joined Moderna on a sabbatical from the Ragon Institute to lead the immunology group within Infectious Disease Research.{{Cite web |title=Personal LinkedIn page of Dr. Galit Alter. |url=https://www.linkedin.com/in/galit-alter-398184252/}}